Bachem Holding AG
SIX:BANB

Watchlist Manager
Bachem Holding AG Logo
Bachem Holding AG
SIX:BANB
Watchlist
Price: 57.8 CHF 1.23%
Market Cap: 4.3B CHF
Have any thoughts about
Bachem Holding AG?
Write Note

Bachem Holding AG
Pre-Tax Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Bachem Holding AG
Pre-Tax Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Pre-Tax Income CAGR 3Y CAGR 5Y CAGR 10Y
Bachem Holding AG
SIX:BANB
Pre-Tax Income
CHf127.9m
CAGR 3-Years
4%
CAGR 5-Years
16%
CAGR 10-Years
15%
Siegfried Holding AG
SIX:SFZN
Pre-Tax Income
CHf165.5m
CAGR 3-Years
25%
CAGR 5-Years
17%
CAGR 10-Years
N/A
Lonza Group AG
SIX:LONN
Pre-Tax Income
CHf699m
CAGR 3-Years
9%
CAGR 5-Years
-1%
CAGR 10-Years
12%
Tecan Group AG
SIX:TECN
Pre-Tax Income
CHf99.4m
CAGR 3-Years
-17%
CAGR 5-Years
5%
CAGR 10-Years
N/A
PolyPeptide Group AG
SIX:PPGN
Pre-Tax Income
-€58.2m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
SKAN Group AG
SIX:SKAN
Pre-Tax Income
CHf32.8m
CAGR 3-Years
34%
CAGR 5-Years
42%
CAGR 10-Years
N/A
No Stocks Found

Bachem Holding AG
Glance View

Market Cap
4.3B CHF
Industry
Life Sciences Tools & Services

In the heart of the Swiss pharmaceutical industry, Bachem Holding AG has carved out a distinct niche as a leading player in the peptide manufacturing landscape. Founded by Peter Grogg in 1971, Bachem has grown from a modest laboratory venture into a global powerhouse with an exceptional focus on peptides and oligonucleotide development. These biomolecules, small chains of amino acids, and nucleotides respectively, play crucial roles in modern therapeutics, acting as key components in drug design for treating various ailments. From its headquarters in Bubendorf, Switzerland, Bachem leverages cutting-edge technologies to enhance the purity and scalability of peptide production, meeting the demand from pharmaceutical and biotechnology companies worldwide. By establishing a robust supply chain and maintaining high standards of quality control, the company ensures the reliability and success of its partnerships. At the core of Bachem's business model is the offering of customized products and services tailored to client-specific needs, ranging from research-grade to commercial-scale production. The company generates revenue through long-term contracts and ongoing relationships with key players in the global pharmaceutical industry. As drug discovery advances, Bachem’s role in providing essential active pharmaceutical ingredients (APIs) becomes increasingly central, facilitating the development of novel therapies. The company also invests heavily in research and development to continuously refine its manufacturing processes and expand its service portfolio. By marrying scientific expertise with strategic foresight, Bachem not only anchors itself in the present pharmaceutical landscape but also positions itself for future growth in the biotechnology sector.

BANB Intrinsic Value
88.42 CHF
Undervaluation 35%
Intrinsic Value
Price

See Also

What is Bachem Holding AG's Pre-Tax Income?
Pre-Tax Income
127.9m CHF

Based on the financial report for Jun 30, 2024, Bachem Holding AG's Pre-Tax Income amounts to 127.9m CHF.

What is Bachem Holding AG's Pre-Tax Income growth rate?
Pre-Tax Income CAGR 10Y
15%

Over the last year, the Pre-Tax Income growth was 18%. The average annual Pre-Tax Income growth rates for Bachem Holding AG have been 4% over the past three years , 16% over the past five years , and 15% over the past ten years .

Back to Top